Novartis Doubles Up In Optogenetics With Arctos Buy
Complements Acquisition Of Vedere Last Year
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.
